The Fourth Hospital Affiliated to Soochow University, Wuxi, Jiangsu, China.
Chin Med J (Engl). 2013 Aug;126(16):3035-8.
B7-H3 has been widely studied in the context of tumor progression in recent years, and behaves as a tumor cell marker in a variety of tumors including colorectal carcinoma. The mechanism of B7-H3 in tumor progression is complicated and not clear yet. Studies have revealed that B7 family molecules are expressed on infiltrated lymphocytes as well as tumor cells in tumor microenvironment, which indicates that different expression pattern may lead to different clinical outcomes.
The expression of B7-H3 was detected in tissues of 98 colorectal carcinoma patients by using immunohistochemistry. Then the expression of B7-H3 on CD3(+) T lymphocytes isolated from fresh cancer tissues of 12 colorectal carcinoma patients was analyzed by flow cytometry assay. The relationship between the expression of B7-H3 on CD3(+) T lymphocytes and patients' clinical pathological parameters was demonstrated with statistical analysis.
Patients with more CD3(+) T cell infiltration survived much longer than patients with less CD3(+) T cell infiltration (P < 0.05); B7-H3 was highly expressed by infiltrating CD3(+) T lymphocytes in colorectal carcinoma tissues. The expression of B7-H3 was found to be significantly related with lymph node metastasis status (P < 0.05), but not with the patient's gender, age, tumor size, differentiation degree, depth of tumor invasion, Dukes' stage, distant metastasis and whether or not mucinous adenocarcinoma was present (P > 0.05). Moreover, the survival time of patients with low expression of B7-H3 was obviously longer than those of high B7-H3 expression patients, but the seven-year survival rate showed no difference between the high and low B7-H3 expression patients (P > 0.05).
The negative costimulatory molecule B7-H3 on infiltrating CD3(+) T lymphocytes in colorectal carcinoma bears importance in the clinical pathological progress and prognosis of colorectal carcinoma.
近年来，B7-H3 在肿瘤进展的背景下得到了广泛研究，并且在包括结直肠癌在内的多种肿瘤中作为肿瘤细胞标志物。B7-H3 在肿瘤进展中的机制复杂且尚不明确。研究表明，B7 家族分子在肿瘤微环境中的浸润淋巴细胞和肿瘤细胞上表达，这表明不同的表达模式可能导致不同的临床结果。
应用免疫组织化学方法检测 98 例结直肠癌患者组织中 B7-H3 的表达，然后应用流式细胞术分析 12 例结直肠癌患者新鲜癌组织中分离的 CD3(+)T 淋巴细胞上 B7-H3 的表达，用统计学方法分析 CD3(+)T 淋巴细胞上 B7-H3 的表达与患者临床病理参数的关系。
CD3(+)T 细胞浸润较多的患者比 CD3(+)T 细胞浸润较少的患者存活时间更长（P < 0.05）；B7-H3 在结直肠癌组织中高表达于浸润的 CD3(+)T 淋巴细胞。B7-H3 的表达与淋巴结转移状态显著相关（P < 0.05），而与患者的性别、年龄、肿瘤大小、分化程度、肿瘤浸润深度、Dukes 分期、远处转移以及是否存在黏液腺癌无关（P > 0.05）。此外，B7-H3 低表达患者的生存时间明显长于 B7-H3 高表达患者，但 B7-H3 高表达和低表达患者的 7 年生存率无差异（P > 0.05）。
结直肠癌浸润 CD3(+)T 淋巴细胞上的负共刺激分子 B7-H3 与结直肠癌的临床病理进展和预后有关。
